Core Viewpoint - Skyhawk Therapeutics has entered into a strategic research collaboration with Merck KGaA to develop novel RNA-targeted therapeutics for specific neurological indications with high unmet medical needs [1][3]. Group 1: Collaboration Details - The collaboration will utilize Skyhawk's proprietary SkySTAR® platform to identify small molecule candidates targeting specific RNA sites designated by Merck [3]. - Skyhawk will lead the discovery and preclinical development, while Merck will take responsibility for further development and commercialization after option exercise [3]. - The total transaction value exceeds $2 billion, with Skyhawk eligible for milestone payments and tiered royalties on commercial sales [3]. Group 2: Company Background and Financials - Skyhawk has raised over $679 million, with more than $479 million coming from upfront payments from pharmaceutical collaborations [5]. - The company has established partnerships with major pharmaceutical firms, including Merck, MSD, BMS, Biogen, Takeda, and Vertex, with significant upfront payments [5]. - In 2024, Ipsen is expected to enter into an $1.8 billion collaboration with Skyhawk [5]. Group 3: Research Focus - Skyhawk is focusing on neuroscience, with a lead program in phase 2/3 aimed at treating Huntington's disease by reducing the production of mutant HTT [6]. - In addition to neuroscience, Skyhawk is developing preclinical projects targeting lymphoma and fibrosis [6].